✦ LIBER ✦

415 Investigating the Role of HER4 in Relation to Trastuzumab Treatment and Resistance in HER2 Positive Breast Cancer

✍ Scribed by Nafi, S. Mohd; Kong, A.; Gijsen, M.; Kramer-Marek, G.; Capala, J.

Book ID: 123505485
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 55 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(12)72213-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

123 ROLE OF RADIATION INDUCED ß1-INTEGRI

123 ROLE OF RADIATION INDUCED ß1-INTEGRIN EXPRESSION IN TRASTUZUMAB RESISTANCE IN HER-2 POSITIVE BREAST CANCER

✍ Thoms, J.; Sabri, S.; Lesniak, D.; Murray, D.; Abdulkarim, B. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 31 KB

Immunohistochemical expression of HER1,

Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

✍ Kan Yonemori; Koji Tsuta; Chikako Shimizu; Yutaka Hatanaka; Akihiro Hirakawa; Ma 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

The role of trastuzumab in the managemen

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review

✍ Yutaka Tokuda; Yasuhiro Suzuki; Yuki Saito; Shinobu Umemura 📂 Article 📅 2009 🏛 Springer Japan 🌐 English ⚖ 234 KB

317: Analysis of HER2 amplification and

317: Analysis of HER2 amplification and IGF-IR expression in CETCs and its possible association with resistance to trastuzumab in HER2 positive breast cancers

✍ Zimon, D.; Pizon, M.; Pachmann, U.; Pachmann, K. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Cost-effectiveness analysis of trastuzum

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

PI3KCAmutations and/or PTEN loss in Her2

PI3KCAmutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy

✍ Barbareschi, Mattia; Cuorvo, Lucia Veronica; Girlando, Salvatore; Bragantini, Em 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 480 KB